Dynaflow Resolve used in reserach showing potential new ways to treat pain
Chronic pain is a condition that affects approximately 20 percent of the adult population. Today, poor efficacy and…
Chronic pain is a condition that affects approximately 20 percent of the adult population. Today, poor efficacy and…
We are excited to announce the relaunch of our high-precision ion channel screening platform Dynaflow® Resolve. With Dynaflow…
Fluicell’s R&D team is demonstrating important progress in the Company’s type 1 diabetes therapeutics in vitro development and…
We look forward to meeting everyone in the tissue engineering and regenerative medicine community in Manchester for TERMIS-EU…
The cell membrane plays a crucial role for the function of biological cells. Understanding how cell-like membrane compartments…
Today, February 24 2023, Fluicell publishes the Q4 Year-end report for the period January to December, 2022. The…
Spheroids are a powerful tool for in vitro tissue and disease modeling, with multiple applications across cancer and…
Do you want to be part of an innovative team pushing the boundaries in 3D bioprinting, engineered tissue-based…
2022 has been a busy year for us at Fluicell. Not only have we this year released Biopixlar…